BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Feb 2, 2015
Emerging Company Profile

Three's company

How the serotonin component of Neurovance's ADHD candidate could set it apart
BioCentury | Jun 3, 2013
Clinical News

Amitifadine: Phase IIb/IIIa data

BioCentury | Oct 22, 2012
Clinical News

Amitifadine: Completed Phase IIb/IIIa enrollment

BioCentury | Oct 22, 2012
Finance

Maximizing depression

Euthymics spins out Neurovance; clears way for potential deal in depression
BioCentury | Oct 19, 2012
Company News

Euthymics' Neurovance spinout raises $7M

BioCentury | Dec 5, 2011
Emerging Company Profile

Euthymics: Balancing act

Euthymics: Correct balance of triple reuptake inhibition will be key in MDD
Items per page:
1 - 6 of 6